Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS) (Q66083827)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS) |
clinical trial |
Statements
Testing the Ability of Pembrolizumab to Alter the Tumor Immune MicroEnvironment (TIME) of High Risk DCIS (English)
0 references
12 December 2016
0 references
March 2019
0 references
48
0 references
18 year
0 references